Cargando…

Neuropsychiatric Disorders in Chronic Kidney Disease

Neuropsychiatric conditions including depression, anxiety disorders, and cognitive impairment are prevalent in patients with chronic kidney disease (CKD). These conditions often make worse the quality of life and also lead to longer hospitalizations and higher mortality. Over the past decades, some...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simões e Silva, Ana Cristina, Miranda, Aline Silva, Rocha, Natalia Pessoa, Teixeira, Antônio Lúcio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707423/ https://www.ncbi.nlm.nih.gov/pubmed/31474869 http://dx.doi.org/10.3389/fphar.2019.00932

Ejemplares similares

Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders
por: de Miranda, Aline Silva, et al.
Publicado: (2020)

Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies
por: Rocha, Natália Pessoa, et al.
Publicado: (2015)

Renin angiotensin system in liver diseases: Friend or foe?
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2017)

Frequency of overweight and obesity in children and adolescents with autism and attention deficit/hyperactivity disorder
por: Kummer, Arthur, et al.
Publicado: (2016)

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders
por: Scarante, Franciele F., et al.
Publicado: (2021)

The role of maternal obesity in the risk of neuropsychiatric disorders
por: Rivera, Heidi M., et al.
Publicado: (2015)

Editorial: The Role of the Renin-Angiotensin System in the Central Nervous System
por: Rocha, Natalia P., et al.
Publicado: (2021)

From Autism to Eating Disorders and More: The Role of Oxytocin in Neuropsychiatric Disorders
por: Romano, Adele, et al.
Publicado: (2016)

Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update
por: Asgharian, Parina, et al.
Publicado: (2022)

Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside
por: Bian, Yaqi, et al.
Publicado: (2020)

Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
por: Fang, Yu, et al.
Publicado: (2023)

Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin
por: Theoharides, Theoharis C., et al.
Publicado: (2015)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Interactions between Cytokines, Congenital Anomalies of Kidney and Urinary Tract and Chronic Kidney Disease
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2013)

Recent Advances in CNS P2X7 Physiology and Pharmacology: Focus on Neuropsychiatric Disorders
por: Bhattacharya, Anindya
Publicado: (2018)

Editorial: 5-HT(2A/2B/2C) Receptors, Memory, and Neuropsychiatric Disorders
por: Gasbarri, Antonella, et al.
Publicado: (2016)

What Acute Stress Protocols Can Tell Us About PTSD and Stress-Related Neuropsychiatric Disorders
por: Musazzi, Laura, et al.
Publicado: (2018)

Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders
por: Chen, Qian, et al.
Publicado: (2021)

Renin-angiotensin system in the central nervous system: focus on Huntington’s disease
por: de Miranda, Aline Silva, et al.
Publicado: (2023)

Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?
por: Smith, Craig M., et al.
Publicado: (2014)

Chemokines as Potential Markers in Pediatric Renal Diseases
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2014)

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease
por: Geerts, Hugo, et al.
Publicado: (2013)

Redox Signaling in Chronic Kidney Disease-Associated Cachexia
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2023)

Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia
por: Ng, Kok Pin, et al.
Publicado: (2019)

Roles for Exosome in Various Kidney Diseases and Disorders
por: Thongboonkerd, Visith
Publicado: (2020)

Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
por: Butelman, Eduardo R., et al.
Publicado: (2015)

The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease
por: Huang, Yinghui, et al.
Publicado: (2022)

Neuropsychiatric consequences of cardiovascular medications
por: Huffman, Jeff C., et al.
Publicado: (2007)

Editorial: Neuroinflammatory and oxidative/nitrosative pathways in neuropsychiatric and neurological diseases and their possible neuropharmacological regulation, volume I
por: Pereira, Marta P., et al.
Publicado: (2022)

Editorial: Neuroinflammatory and oxidative/nitrosative pathways in neuropsychiatric and neurological diseases and their possible neuropharmacological regulation, Volume II
por: Pereira, Marta P., et al.
Publicado: (2023)

Mitochondrial Targeting of Herbal Medicine in Chronic Kidney Disease
por: Li, Qing, et al.
Publicado: (2021)

Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease
por: Yan, Zhonghong, et al.
Publicado: (2021)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
por: Butelman, Eduardo R., et al.
Publicado: (2015)

Serum levels of angiotensin converting enzyme as a biomarker of liver fibrosis
por: Miranda, Aline Silva, et al.
Publicado: (2017)

Cardiovascular Toxicity Induced by Chronic Vincristine Treatment
por: Herradón, Esperanza, et al.
Publicado: (2021)

Dysfunctional mitochondrial processes contribute to energy perturbations in the brain and neuropsychiatric symptoms
por: Büttiker, Pascal, et al.
Publicado: (2023)

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

Oxidative Stress in Microbial Diseases: Pathogen, Host, and Therapeutics
por: Novaes, Rômulo Dias, et al.
Publicado: (2019)

Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease
por: Zhao, Mingming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3c7r62lhccl8n050uvr5drjmij